Ann Intern Med

1. 
   Summary for Patients: Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay.
   Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-25-04689.
   

   >> Share

   
   
2. HAYES KN, Harris DA, McConeghy KW, Grove LR, et al
   Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay : A Target Trial Emulation.
   Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-25-04689.
   

   >> Share

   
   

   
   BMC Pediatr

3. BWADE MA, Olowo S, Nakawuki A, Namubiru E, et al
   Factors contributing to incomplete vaccination among children aged 12 to 59 months in Mbale city, Eastern Uganda: a caregivers and health workers' perspective.
   BMC Pediatr. 2026 Jun 16. doi: 10.1186/s12887-026-07132.
   

   >> Share

   
   

   
   BMJ

4. SASIENI P, Rix J
   Vaccination is helping to eliminate cervical cancer in several countries, and continued surveillance is essential.
   BMJ. 2026;393:e304038.
   

   >> Share

   
   
5. SORGHO H, Rouamba T, Natama HM, Tinto H, et al
   Advances in the development of malaria vaccines.
   BMJ. 2026;393:e084166.
   

   >> Share

   
   
6. TAYLOR L
   Dengue: Brazil suspends rollout of new vaccine after two deaths.
   BMJ. 2026;393:e205610.
   

   >> Share

   
   
7. MAHASE E
   Meningitis B: UK launches vaccine programme to protect students after fatal outbreaks.
   BMJ. 2026;393:e567368.
   

   >> Share

   
   

   
   J Immunol

8. CIMINO JL, Moshkani S, Bailey JT, Rexhouse C, et al
   Compensatory relationships determine the impact of TGF-beta on the humoral immune response to hepatitis B surface antigen.
   J Immunol. 2026;215:vkag129.
   

   >> Share

   
   
9. NGUYEN AT, Fong KD, Ravesloot-Chavez MM, Pham V, et al
   Parenteral vaccination protects against mucosal Salmonella infection by inducing liver tissue resident memory CD4 T cells.
   J Immunol. 2026;215:vkag138.
   

   >> Share

   
   
10. NOGIMORI T, Okina Y, Masuta Y, Kumamoto M, et al
    Sustained antigen-specific CD8+ T cell immunity post-mRNA booster requires notch pathway activation.
    J Immunol. 2026;215:vkag074.
    

    >> Share

    
    

    
    J Infect

11. DONG S, Li M, Huo D, Zhao H, et al
    Impact of EV-A71 vaccination and non-pharmaceutical interventions on hand, foot, and mouth disease: A 14-year interrupted time series analysis.
    J Infect. 2026;93:106795.
    

    >> Share

    
    

    
    J Infect Dis

12. BEDSAUL-FRYER JR, Mbulaiteye SM
    Selective Immune Tolerance: A Unifying Mechanism Linking Heavy Malaria Exposure, Waning Vaccine Antibodies, and Burkitt Lymphoma.
    J Infect Dis. 2026 Jun 18:jiag312. doi: 10.1093.
    

    >> Share

    
    
13. CHAN AKP, Brockhurst JK, Liu L, Ghimire S, et al
    Distinct Humoral Response Development to Measles Virus across Vaccine Platforms.
    J Infect Dis. 2026 Jun 17:jiag309. doi: 10.1093.
    

    >> Share

    
    
14. MCKEAND SA, Bencomo FR, Soc A, Jones RA, et al
    Investigation of correlates of protection against gonococcal infection by comparative immunoprofiling of responses in experimental and clinical studies.
    J Infect Dis. 2026 Apr 29:jiag216. doi: 10.1093.
    

    >> Share

    
    
15. NURMI V, Hedman L, Vapalahti K, Hepojoki J, et al
    Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations.
    J Infect Dis. 2026;233:e1374-e1385.
    

    >> Share

    
    
16. TEIXEIRA AR, Caskey M
    What's Hot in HIV in 2025-A Basic and Translational Science Review from IDWeek 2025.
    J Infect Dis. 2026 Mar 3:jiag135. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

17. AO Z, Vendramelli R, Buyu M, Truong T, et al
    A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin and matrix protein 2 induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse model.
    J Virol. 2026 Jun 16:e0009726. doi: 10.1128/jvi.00097.
    

    >> Share

    
    

    
    JAMA

18. ANDERER S
    ACP, AMA Decry Executive Order to Change Childhood Vaccine Schedule.
    JAMA. 2026 Jun 18. doi: 10.1001/jama.2026.8313.
    

    >> Share

    
    

    
    Lancet

19. PORTNOY A, Burger EA
    HPV vaccination and early declines in cervical cancer deaths.
    Lancet. 2026 Jun 17:S0140-6736(26)01024-X. doi: 10.1016/S0140-6736(26)01024.
    

    >> Share

    
    
20. SASIENI P, Falcaro M
    Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
    Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
    

    >> Share

    
    

    
    Nat Immunol

21. CHEN G, Guo J, Heath J, Prestwood TR, et al
    Human vaccine responses regulated by parallel cytokine pathways.
    Nat Immunol. 2026 Jun 12. doi: 10.1038/s41590-026-02547.
    

    >> Share

    
    
22. AGRAWAL N, Ates LS, Schille SA, Chaturvedi A, et al
    mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.
    Nat Immunol. 2026 Jun 12. doi: 10.1038/s41590-026-02545.
    

    >> Share

    
    
23. MATZ HC, Yu TG, Dixit K, Kikawa C, et al
    mRNA-based influenza vaccine expands the B cell response breadth in humans.
    Nat Immunol. 2026 Jun 15. doi: 10.1038/s41590-026-02569.
    

    >> Share

    
    

    
    Nat Med

24. GELDSETZER P
    Why large-scale randomized trials of live-attenuated shingles vaccination for dementia prevention are urgently needed.
    Nat Med. 2026 Jun 17. doi: 10.1038/s41591-026-04474.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

25. MARITSI D, Neofytou A, Papadimitriou M, Marmarinos A, et al
    Safety and Early Immune Dynamics Following First Dose of the MMR Vaccine in a Toddler Treated With a JAK Inhibitor.
    Pediatr Infect Dis J. 2026 Jun 16. doi: 10.1097/INF.0000000000005274.
    

    >> Share

    
    

    
    PLoS One

26. GEBRETEKLE GB, Lan M, Xi M, Ximenes R, et al
    Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis.
    PLoS One. 2026;21:e0351183.
    

    >> Share

    
    
27. NOREEN K, Noor M, Maryam S, Baig M, et al
    From global to local: Developing a context-specific BeSD-HPV tool through cultural and linguistic adaptation in Pakistan.
    PLoS One. 2026;21:e0350162.
    

    >> Share

    
    
28. GOBEL S, Jacobtorweihe L, Rossig ML, Braatz F, et al
    Stability of the two enveloped viruses NDV LaSota and YF-ZIKprM/E to support process development.
    PLoS One. 2026;21:e0351417.
    

    >> Share

    
    
29. MUHAMMAD-OLODO AO, Asher L
    Understanding factors influencing HPV vaccine uptake among caregivers in Kwara State, Nigeria: A qualitative study.
    PLoS One. 2026;21:e0351659.
    

    >> Share

    
    
30. QADEER AS, Ay N, Paulson W, Rachel J, et al
    Vaccine management systems with a focus on cold chain management and delivery of immunization services in low- and middle-income countries: A scoping review.
    PLoS One. 2026;21:e0350231.
    

    >> Share

    
    
31. ZHANG S, Li Y, Liu M, Yang J, et al
    Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System.
    PLoS One. 2026;21:e0351652.
    

    >> Share

    
    
32. EZECHUKWU C, Ayandipo EO, Osoteku D, Ibrahim R, et al
    Gaps and barriers preventing sustained delivery of HPV vaccination in Kano, Kaduna, and Lagos states: An exploratory qualitative study.
    PLoS One. 2026;21:e0350510.
    

    >> Share

    
    

    
    Science

33. BINLEY J
    An HIV vaccine blueprint.
    Science. 2026;392:1241-1242.
    

    >> Share

    
    

    
    Vaccine

34. SAFARI MS, Gicheru ET, Mburu MW, Makori TO, et al
    Longitudinal evidence of differential pertussis antibody durability following natural infection among vaccinated children living in contrasting malaria transmission settings in coastal Kenya.
    Vaccine. 2026;88:128837.
    

    >> Share

    
    
35. FLORES-VALDEZ MA, Velazquez-Fernandez JB, Vallejo-Cardona AA, Aceves-Sanchez MJ, et al
    In silico comparison of the differential proteome produced by the tuberculosis vaccine candidate BCGDeltaBCG1419c and its parental BCG strain cultured as biofilms or planktonic cells.
    Vaccine. 2026;88:128855.
    

    >> Share

    
    
36. LE MH, Tran ND, Nguyen TTT, Phan TTN, et al
    Willingness to pay for influenza vaccination among the elderly in Vietnam: A triple-bounded dichotomous choice analysis of economic and behavioral determinants.
    Vaccine. 2026;88:128852.
    

    >> Share

    
    
37. XU X, Jiang B, Xiong J, Jiang Y, et al
    Recombinant subunit vaccines against invasive fungal infections: mechanisms, development progress, and therapeutic potential.
    Vaccine. 2026;88:128864.
    

    >> Share

    
    
38. CHRISTOU-ERGOS M, Sabahelzain MM, Bolsewicz KT, Kaufman J, et al
    Australian adults' views on influenza vaccination: Implications for communication and service quality from a qualitative study.
    Vaccine. 2026;88:128846.
    

    >> Share

    
    
39. LEI Q, Lin X, Yao Z, Fu H, et al
    Booster vaccine reduces BCG-primed mice's protection against primary Mycobacterium tuberculosis infection by raising IL-10 levels.
    Vaccine. 2026;88:128841.
    

    >> Share

    
    
40. MBINTA JF, Awuni PMA, Muhammed Basheer ST, Generao HK, et al
    Effectiveness of recombinant zoster vaccine against herpes zoster and postherpetic neuralgia: a systematic review and meta-analysis of post-licensure observational studies.
    Vaccine. 2026;88:128842.
    

    >> Share

    
    
41. ASAGA PM, Kroeger A, Yako A, Makpo J, et al
    Global misinformation, local consequences: conspiracy theory endorsement and a graded association with COVID-19 vaccine refusal across Nigeria.
    Vaccine. 2026;88:128827.
    

    >> Share

    
    
42. ALAMGIR M, Randimbivololona J, Patelisio PN, Tukia O, et al
    Behavioural and social drivers of HPV vaccine uptake in Tonga: a mixed-methods study using the WHO BeSD framework and Talanoa in a Pacific Island setting.
    Vaccine. 2026;88:128843.
    

    >> Share

    
    
43. DA SILVA MARQUES M, de Neri Machado F, Soares NG, Dos Santos NB, et al
    Timor-Leste's immunization journey: progress, challenges, and the road to IA2030 a viewpoint on leaving no child behind.
    Vaccine. 2026;86:128746.
    

    >> Share

    
    
44. DVORKIN J, Pico M, Guinazu G, Crespi MS, et al
    Residual burden of severe RSV disease in infants during the first season of maternal RSVpreF immunization in Argentina: A hospital-based, multicentre, retrospective cohort study.
    Vaccine. 2026;87:128773.
    

    >> Share

    
    
45. LASALA F, Luczkowiak J, Labiod N, Rivas G, et al
    Oral immunization with virus-like particles elicits Ebola virus-specific humoral and cellular immune responses in mice.
    Vaccine. 2026;87:128764.
    

    >> Share

    
    
46. RATISHVILI T, Teodoro LI, Quach HQ, Ovsyannikova IG, et al
    Vitamin A and body weight status do not impact humoral immunity against measles, mumps or rubella in individuals 4 to 18 years old: a cross-sectional cohort study in India.
    Vaccine. 2026;87:128775.
    

    >> Share

    
    
47. BOGLER L, Jantos N, Barnighausen T, Vollmer S, et al
    Corrigendum to "Estimating the effect of measles vaccination on child growth using 191 DHS from 65 low- and middle-income countries" [Vaccine 37 (2019) 5073-5088].
    Vaccine. 2026;88:128813.
    

    >> Share

    
    
48. GEBREMARIAM AG, Genie M, Le H, Regan A, et al
    Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America.
    Vaccine. 2026;88:128825.
    

    >> Share

    
    
49. SPILA-ALEGIANI S, Massari M, Cutillo M, Menniti-Ippolito F, et al
    Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study.
    Vaccine. 2026;88:128806.
    

    >> Share

    
    
50. WONG LP, Alias H, Lee HY
    Impact of confidence in scientific community, manufacturers, and regulatory authorities on acceptance of locally manufactured mRNA vaccines.
    Vaccine. 2026;88:128792.
    

    >> Share

    
    
51. KY SL, Coblentz EG, Swanson E, Shah R, et al
    HPV vaccine: Influencing peer recommendations through information provision at no-cost vaccine clinics.
    Vaccine. 2026;88:128807.
    

    >> Share

    
    
52. LEITAO JR, Tuani BRV, Vicente IST, Matera JM, et al
    Autologous tumor-based vaccines in canine oncology: a systematic review of safety, immunogenicity, and therapeutic potential.
    Vaccine. 2026;88:128836.
    

    >> Share

    
    
53. BELLO AM, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, et al
    Differential immune responses elicited by two tetravalent epitope-based DNA vaccines differently designed for human hand-foot-and-mouth disease.
    Vaccine. 2026;88:128824.
    

    >> Share

    
    
54. LUTZ CS, Cox SN, Courtney LP, Paulenich A, et al
    Corrigendum to "Impact of simultaneous administration on immune responses to vaccines routinely recommended for use during pregnancy: A targeted literature review" [Vaccine 79 (2026) 128408].
    Vaccine. 2026;88:128812.
    

    >> Share

    
    
55. CORPUZ GS, Sidhu AS, Konig DJ, Waljee JF, et al
    On the implications of shifting Hepatitis B vaccine policy for surgical patients.
    Vaccine. 2026;88:128791.
    

    >> Share

    
    
56. ZHANG L, Li K, Li Y, Fan C, et al
    Adverse events following immunization with human papillomavirus vaccine: post-marketing surveillance in China, 2021-2024.
    Vaccine. 2026;88:128826.
    

    >> Share

    
    
57. BUSH C, Desai S, Wang H, Hsu WC, et al
    Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023.
    Vaccine. 2026;88:128821.
    

    >> Share

    
    
58. LAAKE I, Feiring B, Sorup S, Englund H, et al
    Infectious disease hospitalization rates before and after introduction of vaccine against human papillomavirus in Denmark, Norway, and Sweden: controlled interrupted time series analyses.
    Vaccine. 2026;88:128851.
    

    >> Share

    
    
59. HADDISON E, Nebongo D, Amponsah-Dacosta E
    From community mobilisation to school vaccination: experiences from Cameroon's first Expanded Programme on Immunisation-led school-based HPV campaign.
    Vaccine. 2026;88:128848.
    

    >> Share

    
    
60. RICKE IJ, Ward C, Spaulding AB, Sherwood NE, et al
    Caregiver COVID-19 vaccine status and its influence on pediatric vaccination decisions in a US cohort.
    Vaccine. 2026;88:128847.
    

    >> Share

    
    

    
    Virology

61. MANDVIWALA AS, Liman K, Huckriede ALW, Mishra AC, et al
    Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route.
    Virology. 2026;623:111007.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share